105 related articles for article (PubMed ID: 21537035)
21. Detection of early stage ovarian cancer in a large community cohort.
Suh-Burgmann EJ; Alavi M
Cancer Med; 2019 Nov; 8(16):7133-7140. PubMed ID: 31568690
[TBL] [Abstract][Full Text] [Related]
22. ErbB-3 predicts survival in ovarian cancer.
Tanner B; Hasenclever D; Stern K; Schormann W; Bezler M; Hermes M; Brulport M; Bauer A; Schiffer IB; Gebhard S; Schmidt M; Steiner E; Sehouli J; Edelmann J; Läuter J; Lessig R; Krishnamurthi K; Ullrich A; Hengstler JG
J Clin Oncol; 2006 Sep; 24(26):4317-23. PubMed ID: 16896008
[TBL] [Abstract][Full Text] [Related]
23. Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study.
Fauvet R; Boccara J; Dufournet C; David-Montefiore E; Poncelet C; Daraï E
Cancer; 2004 Mar; 100(6):1145-51. PubMed ID: 15022280
[TBL] [Abstract][Full Text] [Related]
24. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma.
Engelen MJ; Kos HE; Willemse PH; Aalders JG; de Vries EG; Schaapveld M; Otter R; van der Zee AG
Cancer; 2006 Feb; 106(3):589-98. PubMed ID: 16369985
[TBL] [Abstract][Full Text] [Related]
25. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
[TBL] [Abstract][Full Text] [Related]
26. Comparison of symptoms and presentation of women with benign, low malignant potential and invasive ovarian tumors.
Olsen CM; Cnossen J; Green AC; Webb PM
Eur J Gynaecol Oncol; 2007; 28(5):376-80. PubMed ID: 17966216
[TBL] [Abstract][Full Text] [Related]
27. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
28. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.
Fishman DA; Cohen L; Blank SV; Shulman L; Singh D; Bozorgi K; Tamura R; Timor-Tritsch I; Schwartz PE
Am J Obstet Gynecol; 2005 Apr; 192(4):1214-21; discussion 1221-2. PubMed ID: 15846205
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer.
van Nagell JR; DePriest PD; Reedy MB; Gallion HH; Ueland FR; Pavlik EJ; Kryscio RJ
Gynecol Oncol; 2000 Jun; 77(3):350-6. PubMed ID: 10831341
[TBL] [Abstract][Full Text] [Related]
30. Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Dilley J; Burnell M; Gentry-Maharaj A; Ryan A; Neophytou C; Apostolidou S; Karpinskyj C; Kalsi J; Mould T; Woolas R; Singh N; Widschwendter M; Fallowfield L; Campbell S; Skates SJ; McGuire A; Parmar M; Jacobs I; Menon U
Gynecol Oncol; 2020 Aug; 158(2):316-322. PubMed ID: 32561125
[TBL] [Abstract][Full Text] [Related]
31. Women's awareness of ovarian cancer risks and symptoms.
Lockwood-Rayermann S; Donovan HS; Rambo D; Kuo CW
Am J Nurs; 2009 Sep; 109(9):36-45; quiz 46. PubMed ID: 19704232
[TBL] [Abstract][Full Text] [Related]
32. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
[TBL] [Abstract][Full Text] [Related]
33. Predictive value of symptoms for early detection of ovarian cancer.
Rossing MA; Wicklund KG; Cushing-Haugen KL; Weiss NS
J Natl Cancer Inst; 2010 Feb; 102(4):222-9. PubMed ID: 20110551
[TBL] [Abstract][Full Text] [Related]
34. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study.
Paramasivam S; Tripcony L; Crandon A; Quinn M; Hammond I; Marsden D; Proietto A; Davy M; Carter J; Nicklin J; Perrin L; Obermair A
J Clin Oncol; 2005 Sep; 23(25):5938-42. PubMed ID: 16087942
[TBL] [Abstract][Full Text] [Related]
35. Predictive value of symptoms for ovarian cancer: comparison of symptoms reported by questionnaire, interview, and general practitioner notes.
Lim AW; Mesher D; Gentry-Maharaj A; Balogun N; Jacobs I; Menon U; Sasieni P
J Natl Cancer Inst; 2012 Jan; 104(2):114-24. PubMed ID: 22247022
[TBL] [Abstract][Full Text] [Related]
36. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study.
Vernooij F; Heintz AP; Witteveen PO; van der Heiden-van der Loo M; Coebergh JW; van der Graaf Y
J Natl Cancer Inst; 2008 Mar; 100(6):399-406. PubMed ID: 18334710
[TBL] [Abstract][Full Text] [Related]
37. Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer.
Ryerson AB; Eheman C; Burton J; McCall N; Blackman D; Subramanian S; Richardson LC
Obstet Gynecol; 2007 May; 109(5):1053-61. PubMed ID: 17470582
[TBL] [Abstract][Full Text] [Related]
38. Influence of the gynecologic oncologist on the survival of ovarian cancer patients.
Chan JK; Kapp DS; Shin JY; Husain A; Teng NN; Berek JS; Osann K; Leiserowitz GS; Cress RD; O'Malley C
Obstet Gynecol; 2007 Jun; 109(6):1342-50. PubMed ID: 17540806
[TBL] [Abstract][Full Text] [Related]
39. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.
Bačić B; Haller H; Mrklić I; Košta V; Čarić A; Tomić S
Arch Gynecol Obstet; 2013 Jun; 287(6):1219-24. PubMed ID: 23269354
[TBL] [Abstract][Full Text] [Related]
40. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.
Chan JK; Teoh D; Hu JM; Shin JY; Osann K; Kapp DS
Gynecol Oncol; 2008 Jun; 109(3):370-6. PubMed ID: 18395777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
